BD an­nounces an­oth­er ex­pan­sion, this time in San Diego

4 years ago
R&D

Covid-19 roundup: Pfiz­er sues for­mer em­ploy­ee for steal­ing vac­cine se­crets; Eu­ro­pean of­fi­cials rec­om­mend vac­cine ...

4 years ago
Coronavirus

FDA com­mish nom­i­nee's fi­nan­cial dis­clo­sures re­veal a vast web of in­dus­try ties. Will they mat­ter?

4 years ago
People
FDA+

FDA asks court for 55 years to com­plete a FOIA re­quest on the Pfiz­er/BioN­Tech vac­cine

4 years ago
FDA+

FDA hits the red light on an ear­ly-stage AML study af­ter a pa­tient dies

4 years ago
R&D
FDA+

Eu­rope changes its tune on Covid-19 vac­cine IP, ad­vo­cat­ing now for a 'tar­get­ed waiver'

4 years ago
Pharma
Coronavirus

The deal for BeiGene's mas­sive new US man­u­fac­tur­ing and R&D site is com­plete, and it plans to pour in 'sev­er­al ...

4 years ago
Manufacturing

Af­ter a rocky decades-long jour­ney, Take­da’s CMV drug gets FDA OK

4 years ago
FDA+

Mer­ck­'s pause on an HIV pro­gram snow­balls as a Gilead-part­nered tri­al is shoved in­to lim­bo

4 years ago
Deals
R&D

BeiGene gets the ball rolling on its 3rd IPO — and this one is ex­pect­ed to fetch $3B

4 years ago
Financing
China

Tak­ing a leave of ab­sence, Am­pio Phar­ma­ceu­ti­cals CEO pass­es ba­ton to a new board mem­ber; Ax­el Hoos' can­cer biotech ...

4 years ago
Peer Review

Mar­ket­ingRx roundup: Am­gen, Lil­ly, Bio­haven mi­graine brand re­call low, study says; No­var­tis looks to re­make drug ...

4 years ago
Pharma
Marketing

Q&A: Hori­zon CEO Tim Wal­bert goes from C-suite to face of the brand

4 years ago
People
Pharma

Ho­log­ic part­ners with Black women ad­vo­cates on uter­ine fi­broids cam­paign to im­prove di­ag­noses and treat­ment

4 years ago
Pharma
Marketing

J&J’s neu­ro­science re­nais­sance? Janssen R&D chief ready­ing for 'gold­en age'

4 years ago
R&D
Pharma

Drag­on­fly gets Mer­ck on sec­ond TriN­KET can­di­date since 2018 col­lab; Chi­nese eye gene ther­a­py de­vel­op­er nabs $60M

4 years ago
News Briefing

$107B in 2+ years? Pfiz­er’s Covid-19 vac­cine may re­de­fine ‘megablock­buster’ by 2022 — an­a­lyst

4 years ago
Pharma
Coronavirus

Covid-19 roundup: WHO looks to boost pro­duc­tion of an­ti­body tests in low­er-in­come coun­tries; US gov­ern­ment fights to ...

4 years ago
Coronavirus

The lat­est threat to the man­u­fac­tur­ing in­dus­try: sus­pi­cious mal­ware

4 years ago
Manufacturing

FDA ap­proves pricey new treat­ment for ul­tra-rare and ag­gres­sive form of sar­co­ma

4 years ago
Pharma
FDA+

Did Eu­rope blun­der in its Covid vac­cine picks? Pas­cal So­ri­ot points to a po­ten­tial mis­take — and jabs back over ...

4 years ago
Coronavirus

A fledg­ling transpa­cif­ic biotech grabs a launch round to dive in­to on­col­o­gy and au­toim­mune re­search

4 years ago
Financing

Vac­ci­body gets a new name and loads up with near­ly $1B in biobucks for new vac­cine pact with Re­gen­eron

4 years ago
Deals

Eight years and $1.3B lat­er, As­traZeneca fi­nal­ly un­veils Cam­bridge R&D palace

4 years ago
Pharma
First page Previous page 618619620621622623624 Next page Last page
A service from the Financial Times